A Comprehensive Definition for Integrative Oncology

Witt, Claudia M.; Balneaves, Lynda G.; Cardoso, M.J.; Cohen, Lorenzo; Greenlee, Heather; Johnstone, Peter A.S.; Küçük, Ömer; Mailman, Josh; Mao, Jun J.

doi:10.1093/jncimonographs/lgx012

Cited by 193 publications

(178 citation statements)

References 10 publications

Supporting

Mentioning

168

Contrasting

Unclassified

Order By: Relevance

“…'Integrative oncology' better represents the process of care that is provided when patients are receiving integration of interventions such as acupuncture, mindfulness and yoga, and lifestyle counseling in addition to their standard cancer treatments [22]. Recognized the rise and innovation in the integrative oncology area, it is estimated that, on average, about 40% of cancer patients reported current or previous use of 'non-standard' approaches during their cancer treatment [23].…”

Section: Resultsmentioning

confidence: 99%

Integrated oncological treatment in the course of metastatic mammary neoplasia: a complete resolution case

Strangis¹,

Maroccia²,

Fiorentini³

et al. 2019

View full text Add to dashboard Cite

Metastatic breast cancer has a poor prognosis. The validated anticancer drugs used so far are unable to reverse the metastatic spread and consequently the progression of the disease. Recently, it has come to light that the combined use of clinically-relevant anticancer treatments in association with natural substances, acupuncture techniques and adequate nutrition, can lead to the resolution of cases with metastatic diffusion. We herein report the case of a 72-year-old woman who, after a radical mastectomy surgery for breast cancer in 2000 and hormone therapy until 2009, presented a pulmonary recurrence in 2014. For this reason, the patient underwent an integrated therapy, combining the standard oncological treatment with the use of herbal medicine, minerals and mushroom therapy, acupuncture and nutritional counseling. This not only permitted an improvement in her quality of life, with reduction of pain and analgesic intake, but also led to the metabolic disappearance of secondary neoplastic lesions. The case focuses the importance of integrative approaches for cancer patients in a conventional medical setting.

show abstract

Section: Resultsmentioning

confidence: 99%

Integrated oncological treatment in the course of metastatic mammary neoplasia: a complete resolution case

Strangis¹,

Maroccia²,

Fiorentini³

et al. 2019

View full text Add to dashboard Cite

show abstract

“…As per definition, IO "is a patient-centered, evidence-informed field of cancer care that utilizes mind and body practices, natural products, and/or lifestyle modifications from different traditions alongside conventional cancer treatments. Integrative oncology aims to optimize health, quality of life, and clinical outcomes across the cancer care continuum and to empower people to prevent cancer and become active participants before, during, and beyond cancer treatment" [3]. e American Society of Clinical Oncology (ASCO) has recently acknowledged the International Society of Integrative Oncology (SIO) guideline reflecting IO's impact on the improvement of health-related quality of life [4].…”

Section: Introductionmentioning

confidence: 99%

Cost‐Effectiveness of Real‐World Administration of Concomitant Viscum album L. Therapy for the Treatment of Stage IV Pancreatic Cancer

Thronicke

Reinhold

Trott

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. For patients receiving add-on Viscum album L. (VA) treatments for late-stage pancreatic cancer, an improved overall survival (OS) was observed. Only limited information regarding cost-effectiveness (CE) for comparisons between standard of care and standard of care plus add-on VA in stage IV pancreatic cancer treatment is available. The present study assessed the costs and cost-effectiveness of standard of care plus VA (V) compared to standard of care alone (C) for a hospital in Germany. Methods. An observational study was conducted using data from the Network Oncology clinical registry. Patients included had stage IV pancreatic cancer at diagnosis and received C or V treatment in a certified German Cancer Center. Cost and cost-effectiveness analyses (CEA) including the analysis of the incremental cost-effectiveness ratios (ICER) were performed from the hospital’s perspective based on routine data from the financial controlling department and observed data on OS. The primary result of the analysis was tested for robustness in a bootstrap-based sensitivity analysis. Results. 88 patients (C: n = 34; V: n = 54) were included, with a mean age 65.6 years and proportion of male patients 48.9%. Adjusted hospital’s total mean costs for patients from the C and V groups were €10068.97 (over an adjusted mean OS time of 7.1 months) and €12267.94 (over an adjusted mean OS time of 10.6 months), respectively. As to CEA analysis, a relevant total hospital’s savings of €260.81/month mean OS for V patients compared to C was calculated. The costs per additional OS month gained (ICER) with the V treatment compared to C were €628.28. Furthermore, a relevant hospital savings of €915.77 per mean hospital stay and additional costs of €75.09 per mean hospitalization day in the V group were observed compared to C. Conclusion. Based on this CEA analysis, from the hospital’s point of view, the costs per mean month of OS and per mean hospital stay were lower for patients under combinational standard of care plus VA compared to patients receiving standard of care alone for the treatment of stage IV pancreatic cancer. Further prospective cost-effectiveness studies are mandatory to reevaluate our findings.

show abstract

“…Considering the risks of toxicity in pregnancy, the search for new models of care based on whole medical systems, natural products and non-pharmacological therapeutic interventions has been increasingly addressed within the concept of integrative oncology in order to improve the quality of life and survival of these patients by integrating conventional therapy [11,12]. The search strategy for medicinal plants has resulted in the development and production of some anti-cancer agents widely used in oncology practice such as Catharanthus roseus (vincristine, vinblastine and vinorelbine), Taxus brevifolia (taxol and docetaxel), Podophyllum peltatum (etoposide and teniposide) and Camptotheca acuminata (topotecan) [13].…”

Section: Introductionmentioning

confidence: 99%

The Safety of Viscum Album L. in A Murine Model: A Reproductive Toxicity Study

Ghelman¹,

Cernach²,

Ishigai³

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background: The use of antineoplasic drugs in pregnancy poses a huge safety challenge because of the risk of teratogenicity, mutagenicity and carcinogenicity. The rational use of the herbal medicine Viscum album (VA) has shown promising results in several tumor lines as part of the strategy of immunotherapy and anti-angiogenesis in integrative oncology. The safety of intrauterine fetal exposure to VA is however unknown and can be further evidenced for therapeutic doses in pregnant cancer patients.Methods: 47 pregnant Wistar rats and 399 fetuses bred following exposure to VA were investigated. The rats were randomized into five groups. Control group (CG) received no treatment and stress group (SG) received daily vehicle subcutaneous injections alone in same volume as the treatment groups from day zero until the twentieth day of pregnancy. There were three treatments groups: therapeutic dose group (TG) received the usual therapeutic dose (UTD) of 0.013 mg/kg BW; high dose group (HG) received 12.5 mg/kg BW and very high dose group (VHG) received 25mg/kg BW, daily.Results: Weight gain was greater in the rats, placentas and fetuses in the TG and HG compared to SG. Histology of the placentas showed a greater inflammatory process in HG and VHG.Conclusion: Since no cases of abortion, embryotoxicity, natimortality or teratogenicity were found in the fetuses and histology detected no lesions in the tissues evaluated, it is reasonable to conclude that this drug is safe for use in pregnant rats.

show abstract

A Comprehensive Definition for Integrative Oncology

Abstract: This short and comprehensive definition for the term integrative oncology will facilitate a better understanding and communication of this emerging field. This definition will also drive focused and cohesive effort to advance the field of integrative oncology.

Cited by 193 publications

References 10 publications

Integrated oncological treatment in the course of metastatic mammary neoplasia: a complete resolution case

Integrated oncological treatment in the course of metastatic mammary neoplasia: a complete resolution case

Cost‐Effectiveness of Real‐World Administration of Concomitant Viscum album L. Therapy for the Treatment of Stage IV Pancreatic Cancer

The Safety of Viscum Album L. in A Murine Model: A Reproductive Toxicity Study

Contact Info

Product

Resources

About